Evidence map›Paper›PMID 32733094›Full record

ReviewNature reviews. Nephrology2020

The immunology of renal cell carcinoma.

C Marcela Díaz-Montero, Brian I Rini, James H Finke

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05808608 (Efficacy and Safety of First-Line Cadonilimab Plus Axitinib in Patients With Advanced Special Pathological Type Renal Cell Carcinoma), which is not on this map. Cited by 303 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
303citing papers in PubMed, 4 pooled it
24.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05808608 phase1 / phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of First-Line Cadonilimab Plus Axitinib in Patients With Advanced Special Pathological Type Renal Cell Carcinoma: A Prospective, Multi-center, Phase Ib/II Trial

TypeinterventionalSponsorHao ZengRan2023 to 2026Enrolled37ConditionsRenal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell CarcinomaArmsAK104, Axitinib
3 · Its place in the literature

Who cites it

303 citing papers in PubMed, 4 syntheses or guidelines pooled it, 472 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

243 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

C Marcela Díaz-MonteroDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. diazc2@ccf.org.
Brian I RiniVanderbilt University Medical Center, Nashville, TN, USA.
James H FinkeDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. finkej@ccf.org.
Cleveland Clinic Lerner College of Medicine · USVanderbilt University Medical Center · US

Funding

Regulation of MDSC function and traffickingR01CA168488 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI FINKE, JAMES H · 2013 to 2017
$1.9M
Improving adoptive cell therapy by enhancing T cell longevityR21CA188767 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI DIAZ-MONTERO, CLAUDIA MARCELA · 2015 to 2016
$379k
NCI NIH HHS R01 CA168488NCI NIH HHS R21 CA188767
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises several subtypes with unique characteristics. The most common subtype (~70% of cases) is clear-cell RCC. RCC is considered to be an immunogenic tumour but is known to mediate immune dysfunction in large part by eliciting the infiltration of immune-inhibitory cells, such as regulatory T cells and myeloid-derived suppressor cells, into the tumour microenvironment. Several possible mechanisms have been proposed to explain how these multiple tumour-infiltrating cell types block the development of an effective anti-tumour immune response, including inhibition of the activity of effector T cells and of antigen presenting cells via upregulation of suppressive factors such as checkpoint molecules. Targeting immune suppression using checkpoint inhibition has resulted in clinical responses in some patients with RCC and combinatorial approaches involving checkpoint blockade are now standard of care in patients with advanced RCC. However, a substantial proportion of patients do not benefit from checkpoint blockade. The identification of reliable biomarkers of response to checkpoint blockade is crucial to facilitate improvements in the clinical efficacy of these therapies. In addition, there is a need for the development of other immune-based strategies that address the shortcomings of checkpoint blockade, such as adoptive cell therapies.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellHumansImmune Checkpoint InhibitorsImmune ToleranceImmunotherapy, AdoptiveInflammationKidney NeoplasmsMyeloid CellsT-LymphocytesVascular Endothelial Growth Factor ABiomarkers, TumorImmune Checkpoint InhibitorsVascular Endothelial Growth Factor A

Identifiers

PMID32733094
OpenAlexW3045831978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.